<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6F90BFD-2660-441C-A2C4-51EC8ECB6A4C"><gtr:id>B6F90BFD-2660-441C-A2C4-51EC8ECB6A4C</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>fersht</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_A024_1010"><gtr:id>973B4300-B680-4F89-ABA5-7F953D24B1A1</gtr:id><gtr:title>Structural Biology of the tumour suppressor p53 and its complexes and drug discovery.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_A024_1010</gtr:grantReference><gtr:abstractText>The body has defence mechanisms against cancer that centre around a protein called p53. This protein also has important roles in many other biological processes, ranging from fertility to ageing. When p53 receives signals that a cell is becoming cancerous, the protein sets into action a train of events that eventually lead to the cancer cell being destroyed. For cancer cells to survive, the activities of p53 have to be eliminated. About half of human cancers have their p53 being disabled by a mutation, most likely caused by environmental damage or radiation. Not only does the cell lose its natural defence against cancer when p53 is inactivated by mutation, it also loses its susceptibility to treatment by radiotherapy and some chemotherapies that destroy cancer cells by activating p53. Some of the disabled mutants could be reactivated by novel-drugs that we are trying to develop. These drugs will not only kick p53 back into action by itself but also will reinstate radiotherapy and some chemotherapies. Our research, on the one hand, is using our existing knowledge directly to design these new drugs and, on the other hand, to use state-of-the-art methods to study the very complex shape and structure of p53, which will both aid in the design of drugs and help us understand how such proteins can have important roles in so many processes.</gtr:abstractText><gtr:technicalSummary>We are studying proteins that are key to regulating the cell cycle and maintaining the integrity of the genome. Intrinsically disordered domains are crucial, functional components of many proteins, especially those involved in cell signalling and regulation of the cell cycle. The presence of disordered regions prevents those proteins being crystallised for structural studies and they are often too large for complete NMR studies so that solution of their structures is a major challenge. The tumour suppressor p53 is an archetypical example of such a protein, as are its negative regulators MDM2 and MDMX. We solved the structure of p53 in solution using a combination of state-of-the-art NMR spectroscopy, small-angle-x-ray scattering, other biophysical and structural methods, protein engineering and computation. We are now doing the same for MDMX and MDM2, and their complexes with p53. We wish to reconstruct the structure of p53 and its complexes in solution in order to understand the relationship between p53?s structure and activity and how it is regulated by post-translational modification and interaction with other partner proteins. These studies will provide fundamental information on the control of the cell cycle and aid in the development of novel anti-cancer drugs. Elimination of the tumour suppression activities of p53 is common to all cancers. p53 is inactivated directly by mutation in ~70% of types of human cancers and its apoptopic pathways impaired in the remainder. We discovered that some 30-40% of these oncogenic mutants are just temperature sensitive (ts), being active at lower temperatures. Further, wild-type p53 is kinetically unstable by spontaneous denaturation, with a half life of 10-20 minutes at body temperature, and the those oncogenic mutants denature even faster. We have shown that the melting temperature and half-life of ts oncogenic mutants can be raised by small molecules that bind to the native structure. A particular mutant, Y220C, is particularly propitious for study and as a target for therapy because the mutation makes a cavity that appears highly druggable yet is distant from the active sites of p53. By a systematic programme using structural biology, protein engineering and biophysical methods, we are discovering lead compounds for a novel class of anti-cancer drugs that could be used to treat 70-80,000 new cases of cancer per annum worldwide via reactivating Y220C. These studies are a paradigm for how small molecules may be used in general to stabilise proteins whose instability may lead to disease.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2516497</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2864F3D7-70AC-47DB-96A3-964A9F87BB71</gtr:id><gtr:title>Long-range modulation of chain motions within the intrinsically disordered transactivation domain of tumor suppressor p53.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ed440822dd541c7efa8706b5cd232af"><gtr:id>8ed440822dd541c7efa8706b5cd232af</gtr:id><gtr:otherNames>Lum JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>pm_14109_29_22176582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>955CBE08-3692-481B-84D3-211BA79C28DC</gtr:id><gtr:title>Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7f7847864fcf397b5215878a560bd6d"><gtr:id>d7f7847864fcf397b5215878a560bd6d</gtr:id><gtr:otherNames>Melero R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>B4Qgg1MEFMu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C00F474E-1D7D-489E-9AF7-E8576CC89679</gtr:id><gtr:title>A single-molecule characterization of p53 search on DNA.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d5ffde5f2bc841e507b67923452aae4"><gtr:id>4d5ffde5f2bc841e507b67923452aae4</gtr:id><gtr:otherNames>Tafvizi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Rk1M74qfTii</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F94E7D8D-54B0-44D9-9E43-77CB6202EEBD</gtr:id><gtr:title>Mechanism of initiation of aggregation of p53 revealed by F-value analysis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da4986ddd49ef7b9f44694642ebbed8"><gtr:id>3da4986ddd49ef7b9f44694642ebbed8</gtr:id><gtr:otherNames>Wang G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d9d99160c1a8.85475355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00749150-D03F-4F36-9196-B895609D6415</gtr:id><gtr:title>Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da4986ddd49ef7b9f44694642ebbed8"><gtr:id>3da4986ddd49ef7b9f44694642ebbed8</gtr:id><gtr:otherNames>Wang G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d9d90c00bee9.21325771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>872DECF9-5504-43C0-BD71-2EEF5A582917</gtr:id><gtr:title>Electrocatalytic monitoring of metal binding and mutation-induced conformational changes in p53 at picomole level.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af8194678a2d4f846e829c5114cdbdc3"><gtr:id>af8194678a2d4f846e829c5114cdbdc3</gtr:id><gtr:otherNames>Palecek E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>jUW4JSY3n37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D88EE5F-F8B2-4705-937E-B36C2C9B7BB5</gtr:id><gtr:title>Design of a molecular support for cryo-EM structure determination.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/662f0dd817d537bfc0b8c1af9ed657ef"><gtr:id>662f0dd817d537bfc0b8c1af9ed657ef</gtr:id><gtr:otherNames>Martin TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d37114b7559.46788612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D64A6A49-35F1-4F0B-B940-ECE8546B2108</gtr:id><gtr:title>Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>56d9d9394103a8.38142350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4CAF4D0-D98E-432C-8ABD-3531388414AD</gtr:id><gtr:title>Don't waste good methods on bad buffers and ambiguous data.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fb7adef0ce22657c6ddda02c27fcffb"><gtr:id>1fb7adef0ce22657c6ddda02c27fcffb</gtr:id><gtr:otherNames>Huang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14109_29_23329326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B75E2205-45B5-4E7A-B74C-4D320FEAD23C</gtr:id><gtr:title>Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1a132d87b18ba5ebb04320694837d1"><gtr:id>7b1a132d87b18ba5ebb04320694837d1</gtr:id><gtr:otherNames>Arbely E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>fnTLUSJLj8V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50A8F674-DAF3-4055-BDE9-5EF73323F68B</gtr:id><gtr:title>Evaluating Drosophila p53 as a model system for studying cancer mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f119326379946603af68904f5b68bdab"><gtr:id>f119326379946603af68904f5b68bdab</gtr:id><gtr:otherNames>Herzog G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14109_29_23135266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4C94C6F-0531-4971-A063-132E73A5E4AF</gtr:id><gtr:title>2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a62dcf05c10c862cb00ccbd30aa8408"><gtr:id>2a62dcf05c10c862cb00ccbd30aa8408</gtr:id><gtr:otherNames>Bauer MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58bd897a77d8d1.61493398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF8D510A-41D4-4C50-8CB7-4A73241D314E</gtr:id><gtr:title>Stability of p53 homologs.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/365e8411668a1c816fb8dc4f1175c17d"><gtr:id>365e8411668a1c816fb8dc4f1175c17d</gtr:id><gtr:otherNames>Brandt T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14109_29_23112865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F8A0203-C24B-4045-8C32-11A9E8F174EF</gtr:id><gtr:title>Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a62dcf05c10c862cb00ccbd30aa8408"><gtr:id>2a62dcf05c10c862cb00ccbd30aa8408</gtr:id><gtr:otherNames>Bauer MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>58bd89e1a5bc84.16475774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64AC95A9-0047-4682-BAAA-0625F9A05AAB</gtr:id><gtr:title>The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.</gtr:title><gtr:parentPublicationTitle>Annual review of biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4154</gtr:issn><gtr:outcomeId>58bd8a044aecd6.73647899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D675C97A-D475-4256-8AF4-EEF45F0F9D19</gtr:id><gtr:title>Deconvoluting Protein (Un)folding Structural Ensembles Using X-Ray Scattering, Nuclear Magnetic Resonance Spectroscopy and Molecular Dynamics Simulation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36735f99bf933e194c3fbf007ce5706f"><gtr:id>36735f99bf933e194c3fbf007ce5706f</gtr:id><gtr:otherNames>Nasedkin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d9d9bbdc5cf9.39627380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988207A5-531B-4826-AF25-CFABBBE4E6C5</gtr:id><gtr:title>Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb10fc9c59c4712409caddcf226407a"><gtr:id>2cb10fc9c59c4712409caddcf226407a</gtr:id><gtr:otherNames>Natan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>j2MmrM3ymzs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A17C277-2F7B-40EC-834A-1DE9AC2612F2</gtr:id><gtr:title>Profile of Martin Karplus, Michael Levitt, and Arieh Warshel, 2013 nobel laureates in chemistry.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71aa684c0844cc59acddac5e6ffc8e1e"><gtr:id>71aa684c0844cc59acddac5e6ffc8e1e</gtr:id><gtr:otherNames>Fersht AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5461dbef08c525.31865432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB2A958C-A8A6-49F6-A202-938D8500CE30</gtr:id><gtr:title>An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0ddf3e20bdf8523cc89f3b0e11673a"><gtr:id>ec0ddf3e20bdf8523cc89f3b0e11673a</gtr:id><gtr:otherNames>Bromley D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>58bd89c7071286.97027530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4455C934-51B2-42F9-9EE2-585FD9DA739D</gtr:id><gtr:title>Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/975956da1f2786b34701712920bae0e0"><gtr:id>975956da1f2786b34701712920bae0e0</gtr:id><gtr:otherNames>Wilcken R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>56d9d968b05d10.92025091</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_A024_1010</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>